Public biotech in 2021 — the numbers Our latest Data Page shows that in 2021, the 955 companies comprising the public biotech sector generated $242 billion in revenue, a 51% increase over 2020
Fig. 1: Biotech IPO activity since 2011, showing the amount raised and the number of companies going public.The beginnings of what became a long downward spiral in the public biotech index were evident by the end of 2021.Large cap, >$5 billion; mid-cap, $1 billion to $5 billion; small cap, $250 million to $1 billion; microcap, <$250 million.Last year, the entire phalanx of 955 companies comprising the public biotech sector generated $242 billion in revenue.
To put this in perspective, the largest multinational pharmaceutical company, Pfizer, made $81 billion in 2021. Even so, biotech’s $242 billion still represents a 51% increase over 2020 . Much of that increase arose from the influx of a large contingent of biotech companies from Asia. The gains also arose from COVID-19–related programs, with the coffers of small- and mid-cap companies swelling with revenue from a burgeoning number of partnerships or government contracts.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
A proteome-scale map of the SARS-CoV-2–human contactome - Nature BiotechnologyLandscape of molecular contacts: How SARS-CoV-2 communicates with human cells NatureBiotech
Leer más »
Repairing the eye - Nature BiotechnologyRepairing the eye: Companies are pursuing interventions to edit, regenerate and reprogram eye tissue to restore lost vision
Leer más »
Extending fluorescence anisotropy to large complexes using reversibly switchable proteins - Nature BiotechnologyExtending fluorescence anisotropy to large complexes using reversibly switchable proteins
Leer más »
What the COVID-19 pandemic revealed about intellectual property - Nature BiotechnologyThe COVID-19 pandemic dispelled some myths underlying intellectual property policy and revealed how stakeholders can develop policies to accelerate development and ensure access using existing tools and experimenting with open science.
Leer más »
Systematic discovery of recombinases for efficient integration of large DNA sequences into the human genome - Nature BiotechnologySystematic discovery of recombinases for efficient integration of large DNA sequences into the human genome
Leer más »
A comprehensive SARS-CoV-2–human protein–protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets - Nature BiotechnologyA comprehensive SARS-CoV-2–human protein–protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets
Leer más »